Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VH8A
|
|||
| Former ID |
DNC006865
|
|||
| Drug Name |
N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide
|
|||
| Synonyms |
AC1O17NE; CHEMBL425789
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H14N2O2
|
|||
| Canonical SMILES |
CC(=O)NC1=CC=C(C=C1)C(=O)C=CC2=CC=CC=N2
|
|||
| InChI |
1S/C16H14N2O2/c1-12(19)18-15-7-5-13(6-8-15)16(20)10-9-14-4-2-3-11-17-14/h2-11H,1H3,(H,18,19)/b10-9+
|
|||
| InChIKey |
LAXKVXCZXLEVKG-MDZDMXLPSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin beta (TUBB) | Target Info | Inhibitor | [1] |
| Tubulin beta-2 chain (TUBB2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.